Table 3.
Adverse events leading to natalizumab treatment discontinuation (total study cohort, n = 72).
| Adverse event | Number of patients | |
|---|---|---|
| n | % | |
| Airways, lungs, thoracic cavity, and mediastinum | ||
| Dyspnea | 1 | 1.4 |
| Upper airway infection | 2 | 2.8 |
| Alimentary tract | ||
| Abdominal pain | 2 | 2.8 |
| Blood and lymphatic tissue | ||
| Anemia | 1 | 1.4 |
| Leukocytosis | 1 | 1.4 |
| Neutropenia | 1 | 1.4 |
| Thrombocytopenia | 1 | 1.4 |
| Bone, skeletal muscle, and connective tissue | ||
| Backache | 2 | 2.8 |
| Flank pain | 1 | 1.4 |
| Limb pain | 3 | 4.2 |
| Muscle spasticity | 1 | 1.4 |
| Muscle weakness | 4 | 5.6 |
| Occipital pain | 1 | 1.4 |
| Cardiovascular | ||
| Deep venous thrombosis | 1 | 1.4 |
| Palpitation | 1 | 1.4 |
| Tachycardia | 1 | 1.4 |
| General | ||
| Chest pain | 1 | 1.4 |
| Fatigue | 3 | 4.2 |
| Fever | 2 | 2.8 |
| Headache | 1 | 1.4 |
| Shivering | 1 | 1.4 |
| Immune system | ||
| Anaphylactic reaction | 1 | 1.4 |
| Mild allergic reaction | 10 | 13.9 |
| Infections | ||
| Abscess (not at site of injection) | 1 | 1.4 |
| Progressive multifocal leukoencephalopathy (PML) | 2 | 2.8 |
| Unknown infection | 4 | 5.6 |
| Liver and biliary system | ||
| Abnormal liver function test | 6 | 8.3 |
| Hepatic insufficiency | 1 | 1.4 |
| Hyperbilirubinemia | 1 | 1.4 |
| Nervous system | ||
| Cognitive disorders | 1 | 1.4 |
| Tremor | 1 | 1.4 |
| Skin and subcutaneous tissue | ||
| Alopecia | 1 | 1.4 |
| Eczema | 4 | 5.6 |
| Urticaria | 4 | 5.6 |
| Unknown | 28 | 38.9 |